Literature DB >> 20534626

Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.

Sonia Rodríguez-Nóvoa1, Lorena Cuenca, Judit Morello, Mateo Córdoba, Francisco Blanco, Inmaculada Jiménez-Nácher, Vincent Soriano.   

Abstract

OBJECTIVES: To study the correlation between the HLA-B*5701 allele and the single nucleotide polymorphism in HCP5 (rs2395029). PATIENTS AND METHODS: All HIV patients naive for abacavir seen at our institution between September 2007 and December 2008 were prospectively screened for HLA-B*5701. HCP5 rs2395029 genotyping was carried out by allelic discrimination using the TaqMan 5'-nuclease assay. High-resolution HLA class I typing was undertaken using sequence-specific primers.
RESULTS: A total of 245 HIV patients were included in the study. A good correlation between HLA-B*5701 and HCP5 was observed (negative and positive predictive values of 100% and 93%, respectively).
CONCLUSIONS: The use of HCP5 rs2395029 testing could be as useful as HLA-B*5701 typing to prevent the abacavir hypersensitivity reaction. Given that HCP5 testing is cheaper, less time-consuming and easier to perform than HLA typing, it may confidently replace the latter in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534626     DOI: 10.1093/jac/dkq204

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

Review 2.  Abacavir pharmacogenetics--from initial reports to standard of care.

Authors:  Michael A Martin; Deanna L Kroetz
Journal:  Pharmacotherapy       Date:  2013-05-03       Impact factor: 4.705

3.  Cutaneous drug hypersensitivity: immunological and genetic perspective.

Authors:  Kisalay Ghosh; Gautam Banerjee; Asok Kumar Ghosal; Jayoti Nandi
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

4.  LncRNA2Function: a comprehensive resource for functional investigation of human lncRNAs based on RNA-seq data.

Authors:  Qinghua Jiang; Rui Ma; Jixuan Wang; Xiaoliang Wu; Shuilin Jin; Jiajie Peng; Renjie Tan; Tianjiao Zhang; Yu Li; Yadong Wang
Journal:  BMC Genomics       Date:  2015-01-29       Impact factor: 3.969

5.  Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.

Authors:  Mengfei Lu; Cathryn M Lewis; Matthew Traylor
Journal:  BMC Med Genomics       Date:  2017-06-19       Impact factor: 3.063

Review 6.  Long Noncoding RNA HCP5, a Hybrid HLA Class I Endogenous Retroviral Gene: Structure, Expression, and Disease Associations.

Authors:  Jerzy K Kulski
Journal:  Cells       Date:  2019-05-20       Impact factor: 6.600

Review 7.  Developing pharmacogenetic screening methods for an emergent country: Vietnam.

Authors:  Dinh Van Nguyen; Christopher Vidal; Hieu Chi Chu; Sheryl van Nunen
Journal:  World Allergy Organ J       Date:  2019-06-06       Impact factor: 4.084

8.  Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.

Authors:  Cathelijne H van der Wouden; Mandy H van Rhenen; Wafa O M Jama; Magnus Ingelman-Sundberg; Volker M Lauschke; Lidija Konta; Matthias Schwab; Jesse J Swen; Henk-Jan Guchelaar
Journal:  Clin Pharmacol Ther       Date:  2019-06-12       Impact factor: 6.875

9.  Ultra-high resolution HLA genotyping and allele discovery by highly multiplexed cDNA amplicon pyrosequencing.

Authors:  Simon M Lank; Brittney A Golbach; Hannah M Creager; Roger W Wiseman; Derin B Keskin; Ellis L Reinherz; Vladimir Brusic; David H O'Connor
Journal:  BMC Genomics       Date:  2012-08-06       Impact factor: 3.969

Review 10.  Individualization of antiretroviral therapy--pharmacogenomic aspect.

Authors:  Bhavik Dalal; Aruna Shankarkumar; K Ghosh
Journal:  Indian J Med Res       Date:  2015-12       Impact factor: 2.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.